NDC product
ATORVASTATIN CALCIUM
NDC 16714-176 · NORTHSTAR RX LLC
Key facts
| Product NDC | 16714-176 |
|---|---|
| Proprietary name | ATORVASTATIN CALCIUM |
| Nonproprietary name | ATORVASTATIN CALCIUM |
| Substances | ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | NORTHSTAR RX LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA090548 |
| Pharmacologic classes | HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |
| Marketing start | Aug 1, 2021 |
| Marketing end | Oct 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory